RxDoctor Payments Data

Gerard Lumkong, MD

Family Medicine · Encinitas, CANPI 1720001977

Payments from drug & device makers

$318in general payments, 2019–2025

Across 14 payments — averaging $22.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$107
  • Sanofi Pasteur Inc.$50
  • Exact Sciences$37
  • Merck$27
  • GSK$25
  • Abiomed$21
  • plus $50 from 3 others

What the payments were for

  • Food & beverage$318100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)4$107
Sanofi Pasteur Inc.2$50
Exact Sciences2$37
Merck1$27
GSK1$25
Abiomed1$21
Phathom Pharmaceuticals, Inc.1$20
Bayer1$17
Lilly USA, LLC1$14

How this compares

$318 in reported general payments places this provider in the 55th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$216,810
Medicare patients
408
Services billed
2,638

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin59$81,525
EliquisApixaban58$71,506
OzempicSemaglutide30$40,532
RybelsusSemaglutide31$37,035
XareltoRivaroxaban13$19,581
MounjaroTirzepatide15$19,243
FarxigaDapagliflozin Propanediol11$12,884
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$10,390
Atorvastatin Calcium577$5,406
Rosuvastatin Calcium242$5,133
Memantine Hcl69$4,787
Wixela InhubFluticasone Propion/Salmeterol18$3,369
Ezetimibe102$2,858
Levothyroxine Sodium248$2,795
Duloxetine Hcl73$2,744

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$14$19,24315 claims
GSKAnoro Ellipta$25$10,39016 claims
AbbVieSynthroid$107$1,55652 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 10,533 family medicine providers in California.

Other family medicine in Encinitas

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →